Mendus to participate in investor and industry conferences in February

Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will participate in the following upcoming investor and industry conferences:

BIO Capital 2025
Amsterdam, The Netherlands, February 5 – 6, 2025
Mendus CEO Erik Manting will attend

Cell & Gene Therapy Manufacturing Summit 2025
Basel, Switzerland, February 12 – 14, 2025
Mendus CTO Leopold Bertea will hold a presentation about establishing large-scale manufacturing for Mendus’ lead program vididencel and participate in a panel discussion about challenges and solutions in the manufacturing and supply chain of cell therapy products
For more information, please see Cell & Gene Therapy Manufacturing Summit 2025

Biologics Manufacturing Germany
München, Germany, February 18 – 19, 2025
Mendus CTO Leopold Bertea will hold a presentation about establishing large-scale manufacturing for Mendus’ lead program vididencel and participate in a panel discussion about evolving collaboration models between biopharmaceutical companies and manufacturing organizations
For more information, please see Biologics Manufacturing Germany

Datum 2025-02-04, kl 08:00
Källa MFN
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.